NCT04766931View on ClinicalTrials.gov

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
Covid19
Interventions
DRUG

FB2001

Subjects will be administered with FB2001 by intravenous (IV) infusion

DRUG

FB2001 Placebo

Subjects will be administered with FB2001 placebo by intravenous (IV) infusion

Trial Locations (1)

07094

Frontage Clinical Services, Inc., Secaucus

Sponsors
All Listed Sponsors
lead

Frontier Biotechnologies Inc.

INDUSTRY